"ALT-B4 Platform Suggests Potential for Improved Pharmacokinetics"

Alteogen will release the results of an experiment that changes the administration method for antibody-drug conjugates (ADCs). The company emphasized that shifting ADCs from intravenous injection to subcutaneous injection can also help alleviate toxicity issues.

Aerial view of Alteogen headquarters and research institute. Alteogen

Aerial view of Alteogen headquarters and research institute. Alteogen

View original image

Alteogen announced on the 23rd that it will present the results of its ADC subcutaneous injection experiment using its proprietary hyaluronidase platform ALT-B4 at 'World ADC Asia 2026,' which will be held in Seoul this June.


ADCs are therapies that have drawn attention for their strong anticancer effects. Because they contain cytotoxic drugs, managing side effects is considered a key challenge. As a result, there have been ongoing concerns in clinical practice about the limitations in administering sufficient doses.


Alteogen explained that its own research confirmed that the use of ALT-B4 not only enables ADCs to be formulated for subcutaneous injection, but also allows for a more gradual increase in blood concentration. Compared to intravenous administration, the drug is absorbed more slowly, suggesting the potential to reduce side effects caused by toxic compounds.


Traditional ADCs can cause toxicity issues due to the rapid rise in blood concentration following intravenous injection, which is why dosing speed control has commonly been used. In contrast, switching to subcutaneous injection can improve dosing convenience and is expected to provide a more stable pharmacokinetic profile.


Tae Yeon Jeon, CEO of Alteogen, stated, "The subcutaneous formulation using ALT-B4 will drive a shift in ADC administration methods," adding, "We will enhance both patient convenience and the scalability of our platform."


Alteogen is working to expand its SC formulation conversion platform based on ALT-B4. In 2024, the company signed a license agreement with Daiichi Sankyo of Japan for technology to convert ADCs to subcutaneous injection. Daiichi Sankyo is currently applying this technology to its flagship ADC therapy, Enhertu, and is conducting clinical trials for the subcutaneous formulation.



World ADC Asia 2026 is an industry forum in Asia covering every stage from ADC discovery to preclinical and clinical development, manufacturing processes, and next-generation technologies. The event will take place in Seoul from June 9 to 11.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing